President Biden today announced a major partnership between Johnson & Johnson and Merck to manufacture the latest COVID-19 vaccine to be authorized for emergency use in the U.S.

The arrangement includes activating the Defense Production Act to help equip two Merck facilities to produce the Johnson & Johnson vaccine, including a fill-finish facility to fill vials and package shots for distribution. The other facility will produce the vaccine itself.

The arrangement is expected to boost lagging Johnson & Johnson supply issues, which will fall significantly short of an initial goal of delivering 12 million shots by the end of February. Instead, Johnson & Johnson, whose vaccine earned a Food and Drug Administration emergency use authorization over the weekend, revised its expectations to 20 million does by the end of March, and 100 million by June.

Related News Articles

Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…